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Diabetic retinopathy is a common diabetes complica-
tion that threatens the eyesight and may eventually
lead to acquired visual impairment or blindness. While
a substantial heritability has been reported for prolifer-
ative diabetic retinopathy (PDR), only a few genetic risk
factors have been identiﬁed. Using genome-wide sib pair
linkage analysis including 361 individuals with type 1 di-
abetes, we found suggestive evidence of linkage with
PDR at chromosome 10p12 overlapping the CACNB2
gene (logarithm of odds 5 2.73). Evidence of associa-
tion between variants in CACNB2 and PDR was also
found in association analysis of 4,005 individuals with
type 1 diabetes with an odds ratio of 0.83 and P value
of 8.6 3 1024 for rs11014284. Sequencing of CACNB2
revealed two coding variants, R476C/rs202152674 and
S502L/rs137886839. CACNB2 is abundantly expressed
in retinal cells and encodes the b2 subunit of the L-type
calcium channel. Blocking vascular endothelial growth
factor (VEGF) by intravitreous anti-VEGF injections is
a promising clinical therapy to treat PDR. Our data show
that L-type calcium channels regulate VEGF expression
and secretion from retinal pigment epithelial cells (ARPE19)
and support the role of CACNB2 via regulation of VEGF
in the pathogenesis of PDR. However, further genetic
and functional studies are necessary to consolidate the
ﬁndings.
Diabetic retinopathy is the leading cause of vision loss in
adults (1). Diabetic retinopathy is subdivided into a milder
nonproliferative form and a severe form, proliferative
diabetic retinopathy (PDR). The prevalence of PDR in
type 1 diabetes varies between 13% and 50% after 15–
20 years of diabetes duration (2,3). Most individuals who
develop PDR would become blind within 5–10 years with-
out treatment (4); however, strict glycemic control and
photocoagulation (or laser treatment) have been successful
therapies both in the prevention and treatment of PDR
(5,6). However, panretinal photocoagulation has side
effects such as peripheral visual ﬁeld constraints. Injec-
tions targeting the vascular endothelial growth factor
(anti-VEGF) comprise a novel treatment modality for
macular edema and have also been suggested to be a prom-
ising therapy to delay PDR, although they are costly and
require recurrent injections (7,8). Several risk factors have
been identiﬁed for PDR, such as poor glycemic control,
long diabetes duration (2), and high blood pressure (9).
Family studies have further revealed that PDR clusters
in families and our previous data suggested a signiﬁcant
genetic component in the pathogenesis of PDR that was as
high as 52% (10). Nevertheless, only a few genetic risk
factors have been robustly identiﬁed for PDR (11–14).
Therefore, we performed linkage and association analyses
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in individuals with type 1 diabetes to identify novel
susceptibility loci and genes predisposing to PDR and
followed up the ﬁndings in retinal pigmented epithelial
cells. Understanding the role of the genetic variation in the
development of diabetic retinopathy may not only reveal
novel molecular mechanisms but also help us discover
biomarkers and ultimately novel therapies to prevent and
treat the disease.
RESEARCH DESIGN AND METHODS
Overview of the Study Design
This study is part of the ongoing nationwide Finnish
Diabetic Nephropathy (FinnDiane) Study, which since
1997 has studied and collected comprehensive data
from individuals with type 1 diabetes in Finland. The
aim of the study is to identify risk factors for diabetes
complications. The study setting has been described pre-
viously (15). The study protocol was approved by the
Ethics Committee of Helsinki and Uusimaa Health District
as well as the local ethics committees of the participating
centers, and the participants gave their written informed
consent prior to participation. The study was conducted in
accordance with the Declaration of Helsinki as revised in
year 2000. The Ethics Committee of the Pirkanmaa Hos-
pital District (Tampere, Finland) (R05116) gave approval
to derive, culture, and differentiate human embryonic stem
cell (hESC) lines for research.
First, a whole-genome sib pair linkage study in individ-
uals with type 1 diabetes was performed. This was followed
by a candidate gene association analysis of CACNB2 in
genome-wide association study (GWAS) data to search for
association between CACNB2 and PDR in a large case-
control setting. Thereafter, targeted sequencing was per-
formed with the aim to ﬁnd causal variants in the CACNB2
gene region that was identiﬁed by the sib pair linkage study
(Fig. 1).
Study Participants
Whole-Genome Linkage Study
The linkage study included 180 families with at least two
siblings with type 1 diabetes. Altogether 361 individuals
formed 202 sib pairs (Fig. 1 and Table 1). Ophthalmic
records and/or fundus photographs were obtained for
94% of the individuals and used to score the severity of
retinopathy. The Early Treatment of Diabetic Retinopathy
Study (ETDRS) grading scale was used, where 10 represents
no retinopathy and $61 PDR (16). Unaffected control
subjects were deﬁned as those with ETDRS of 10–53E. The
eye with the more severe retinopathy served to assess severity.
After exclusion of individuals without data on retinopathy,
345 individuals with type 1 diabetes remained in 162 sib-
ships of two or more siblings. Nine individuals with di-
abetes were included despite having an age at onset of
diabetes.40 years (up to 53.5 years). Sib pairs comprised
both affected sib pairs (i.e., both with type 1 diabetes and
PDR), discordant sib pairs (both with type 1 diabetes but
only one with PDR), and unaffected sib pairs (both with
type 1 diabetes but neither with PDR).
Sequencing
The sequencing of the CACNB2 gene included altogether
16 familial PDR cases (with a sibling with PDR) and
29 sporadic cases (with an unaffected sibling and no
known family history of PDR) from the families partici-
pating in the linkage study. Only one of the two siblings
was chosen if both siblings in a pair had PDR and shared
the same risk alleles.
Candidate Gene Association Analysis
PDR was deﬁned as laser-treated diabetic retinopathy
based on a patient questionnaire. The analysis included
altogether 4,005 individuals with type 1 diabetes with an
onset of diabetes before the age of 40 years and insulin
treatment initiated within 1 year of the diagnosis of
diabetes and with complete data on PDR and covariates
(sex, age, and diabetes duration) available: 1,997 case
subjects with PDR and 2,008 control subjects without
PDR and at least 15 years’ duration of diabetes.
Replication
Replication was sought in GWAS data for 11,097 individ-
uals with type 2 diabetes from the BioBank Japan Hondo
cluster (17), genotyped with the OmniExpressExome (N5
8,880: 4,839 case subjects with any diabetic retinopathy
and 4,041 control subjects without diabetic retinopathy)
and Illumina 610K array (N 5 2,217: 693 case subjects
with any diabetic retinopathy and 1,524 control subjects
without diabetic retinopathy). Genotype imputation with
1000 Genomes Asian phase 1 reference panel resulted in
7,521,072 single nucleotide polymorphisms (SNPs).
Marker Design and Genotyping
Sib Pair Linkage Analysis
In the sib pair linkage analysis, genomic DNA was
extracted from whole blood using the PUREGENE DNA
Puriﬁcation Kit (Gentra Systems, Minneapolis, MN). The
DNA samples were genotyped using an ABI 3730 DNA
analyzer (Applied Biosystems, Foster City, CA) with ABI
PRISM Linkage Mapping Set MD-10 V2.5 (Généthon map)
at the Institute for Molecular Medicine Finland (FIMM),
Figure 1—Flowchart summarizing study design. The number (n)
refers to the number of individuals in each analysis type.
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Helsinki, Finland. In total, there were 367 autosomal
markers with a mean (SD) interval of 9.6 (4.1) cM and
77.7% heterozygosity.
Candidate Gene Association Analysis
The candidate gene association analysis included GWAS
data of 6,171 individuals. SNP genotyping was performed
in three batches by using HumanCoreExome Bead arrays
12-1.0, 12-1.1, and 24-1.0. Variants were called with zCall
(18). Standard quality control procedures were applied as
previously described (19), resulting in 316,899 SNPs and
6,019 individuals passing the quality control. Related-
ness was then calculated (KING 1.30), and genotype im-
putation was performed with Minimac3/Minimac3-omp
v1.0.14 (20) using 1000 Genomes as reference popula-
tion. We excluded 331 parents, 395 individuals with
age at diabetes onset .40 years, diabetes type other
than type 1 diabetes, or no data on diabetes onset year;
278 individuals with no data on laser treatment avail-
able; and 1,010 control subjects with diabetes dura-
tion ,15 years, resulting in 4,005 individuals in the
analysis. Finally, we extracted SNPs within the CACNB2
gene (chromosome 10p12) or 100 kb upstream and down-
stream of the gene.
Sequencing
The sequencing of the CACNB2 gene (chromosome 10,
base pairs 18660956–18880694) (Human Mar. 2006
Assembly [hg18]) was performed with the NimbleGen
Sequence Capture (http://www.nimblegen.com/products/
seqcap/) sequencing technology. This area was chosen
based on the linkage ﬁnding, starting 100 kb upstream
of D10S548 and ending 10 kb downstream of the end of
CACNB2 (at 18870694). Our primary goal was to identify
variants in the coding exons. For the exons 1–4 outside of
the targeted NimbleGen sequencing area, PCR and se-
quencing were performed with standard procedures, and
the primers used are described in the Supplementary Table
1. MutationTaster was used to evaluate the impact of
putative variants (21).
Targeted Sequencing and Genotyping
The two nonsynonymous missense mutations found in the
sequencing data were veriﬁed with targeted sequencing,
and all available family members were sequenced for these
variants. Thereafter, we genotyped these two variants in
3,052 individuals with type 1 diabetes from FinnDiane,
most of whom were also included in the GWAS, with
TaqMan technology. Predesigned TaqMan assays were
ordered from Life Technologies (Life Technologies, Foster
City, CA). ABI PRISM 7900HT Sequence Detection System
and SDS 2.3 software (Life Technologies) were used for
genotyping and genotype calling. Genotyping success rates
were 96.9% for R476C (rs202152674) and 96.4% for
S502L (rs137886839). New heterozygotes found from the
FinnDiane cohort were veriﬁed with PCR and sequencing.
Molecular Biology and Cell Culture Techniques
Retinal pigmented epithelial cell line ARPE19 was obtained
from ATCC (ATCC CRL-2302). ARPE19 cells were grown in
DMEM-F12 (D6421; Sigma-Aldrich) supplemented with
10% FBS (10270106; Gibco/Life Technologies), penicillin-
streptomycin (15140122; Gibco/Life Technologies),
GlutaMAX Supplement (35050061; Gibco/Life Technolo-
gies), and Normocin (ant-nr-1; InvivoGen). MIO-M1 cells
(Müller glial cell lines derived from adult human retina)
were obtained from Limb’s laboratory (22) and grown in
DMEM (11965092; Thermo Fisher Scientiﬁc), otherwise
similarly to ARPE19 cells. We divided cells 1:4 once per
week and used cells below passage number 30 for experi-
ments. At 24 h before transfection, 0.23 106 cells/sixwell
(CLS3516-50EA; Corning) were plated. siGenome human
CACNB2(783) siRNA-SMART pool (M-008741-01-005)
and siGenome nontargeting siRNA pool (10 mmol/L)
were transfected twice at 48-h intervals with Lipofect-
amine RNAiMAX Transfection Reagent (13778075;
Table 1—Clinical characteristics of the individuals in the linkage study
Variable All No PDR PDR P
Men/N (%) 199/361 (55) 124/231 (54) 68/114 (60) 0.35
Age (years) 41 (11.9) 39.4 (12.0) 44.5 (11.0) 0.0001
Age at onset (years) 16 (11.7) 18.2 (12.2) 10.47 (8.0) ,0.0001
Duration of diabetes (years) 25.4 (12.4) 21.16 (11.17) 33.99 (10.42) ,0.0001
HbA1c (mmol/mol) 69.1 (16.4) 67.7 (16.1) 71.9 (17.3) 0.037
HbA1c (%) 8.5 (1.5) 8.35 (1.48) 8.73 (1.58) 0.037
SBP (mmHg) 137 (19) 133 (17) 144 (20) ,0.0001
DBP (mmHg) 80 (10) 79 (10) 82 (11) 0.014
Mean arterial pressure (mmHg) 100 (12) 99 (12) 104 (13) ,0.0001
ETDRS score 43 (20–61) 35 (10–43) 75 (61–75)
Data aremeans (SD) or median (interquartile range) unless otherwise indicated. All: values among all (N5 361) patients. No PDR (N5 231)
and PDR (N 5 114) columns include only participants with sibs after exclusion of participants without data on PDR. P: P value for
difference between PDR groups, calculated with x2 test for sex and with Welch two-sample t test for the continuous variables. DBP,
diastolic blood pressure; SBP, systolic blood pressure.
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Invitrogen) as per the manufacturer’s recommendations
for potent knockdown. Cell medium was collected 48 h
after the second transfection and spin 3,000 rpm for 5 min
to remove cell debris and stored in280°C for future VEGF
measurement by human VEGF quantikine ELISA kit
(DVE00; R&D systems) as per the manufacturer’s recom-
mendations. Cells were lysed in TRIzol reagent (15596026;
Invitrogen), and RNAs were extracted per the manufac-
turer’s protocol. cDNAs were synthesized using Super-
Script III Reverse Transcriptase (18080093; Invitrogen).
Semiquantitative PCR was done with AmpliTaq Gold
(4486226; Applied Biosystem) and quantitative PCR using
SsoAdvanced Universal SYBR Green Supermix (1725271;
Bio-Rad). Western blot to detect CACNB2 protein in
ARPE19 cells was done by blocking polyvinylidene ﬂuoride
(PVDF) membrane (Trans-Blot Turbo Mini PVDF Transfer
Packs, 1704156; Bio-Rad) in 5% fat-free milk in 1X TBS-
0.05% Tween (P9416; Sigma-Aldrich) overnight at 14°C.
Blocked PVDF membrane was later incubated with the
primary CACNB2 antibody (6C4) (H00000783-M05;
Novus Biologicals) for 1 h at room temperature diluted
1:1,000 in blocking buffer and incubated for 1 h in anti-
mouse IgG,HRP-linked secondary antibody 1:3,000 dilu-
tion in the blocking buffer. The mRNA was extracted from
hESC-derived retinal pigmented epithelium (hESC-RPE)
cultured as previously described (23).
Statistical Analyses
Sib Pair Linkage Analysis
In the sib pair linkage analysis, allele frequencies, Mende-
lian inconsistencies, and relationships were checked with
S.A.G.E. software with the FREQ, PEDCHECK, and RELTEST
options (24). One sib pair was reclassiﬁed as half sibs. The
GENIBD program in S.A.G.E. generated single-point and
multipoint identity-by-descent estimates.
In order to pool information from multiple markers,
we performed multipoint, nonparametric linkage analysis
with SIBPAL (sib pair linkage program) in S.A.G.E. with
modiﬁed Haseman-Elston regression (25) of full-sib pairs
and included duration of diabetes as a covariate. The
binary PDR status was treated as a continuous trait.
Empirical P values by up to 106 permutations were con-
verted to pointwise logarithm of odds (LOD) scores (26).
A LOD score of .2.2 is generally considered suggestive
linkage and an LOD score of.3.6 signiﬁcant linkage (27).
In our study, LOD scores .1.75 represent one false per
scan for experiments involving 400 markers and were
regarded as promising.
Candidate Gene Association Analysis
We estimated the effect of the selected SNPs with minor
allele frequency (MAF)$0.1% around themain linkage peak
by logistic regression corrected for sex, age, and duration
of diabetes, and genotyping batch using RvTests (28), and
limited the variants to those with imputation quality $0.6.
The effective number of independent SNPs was estimated
with Genetic type 1 error calculator (GEC) (29).
Sequencing
For each individual with a mutation found in the sequenc-
ing, we matched four control subjects by age, sex, and
diabetes duration and compared the clinical characteristics
between the groups using t test in R.
Data and Resource Availability
The single-point linkage study results and the signiﬁcant
summary statistics from the CACNB2 candidate gene asso-
ciation study are available in Supplementary Tables 2 and
3. The ethics statement and the informed consent do not
allow sharing of individual-level data.
RESULTS
Linkage Analysis in Sib Pairs
The mean number of generations in the whole-genome
linkage study was 2.1 (2 [93.3%], 3 [5.6%], or 4 [0.6%]), the
mean pedigree size was 5.0 (4 [52.8%], 5 [25.0%], and
6 [9.4%]), and the mean (SD) number of siblings in
each family was 2.6 (1.0). Participants with PDR were
older, had longer duration of diabetes, and higher systolic
and diastolic blood pressure (Table 1). We performed
linkage analysis in sib pairs to identify chromosomal
regions linked to PDR and identiﬁed one microsatellite
(D10S548) in the CACNB2 gene on chromosome 10 with
a suggestive single-point LOD score of 2.73 (P 5 1.96 3
1024) and a multipoint LOD score of 1.85 (P 5 0.0017)
(Table 2 and Fig. 2). Evidence of linkage was also found on
chromosome 19 with a multipoint LOD score of 2.69 and
3.01 (D19S210), but the single-point LOD score was non-
signiﬁcant (Supplementary Table 2).
Candidate Gene Association Analysis of CACNB2
The candidate gene association study was performed in
order to examine whether the area under the linkage peak
on chromosome 10 would also show association with PDR
in the GWAS data. The logistic regression showed that
197 SNPs out of 3,528 SNPs with MAF $0.1% had a P
value,0.05 and 33 SNPs a P value,0.01 (Supplementary
Table 3). The SNP with the lowest P value of 8.63 1024 for
association with PDR was a common SNP, rs11014284,
with an odds ratio of 0.83 (95% CI 0.74–0.92) (MAF 5
Table 2—Summary of the nonparametric linkage result for
PDR on the regions showing signiﬁcant or suggestive
evidence of linkage (LOD score >1.75)
Chromosome Marker
Map position
(cM)
LOD
Single
point Multipoint
10 * 41.2 * 2.05
10 D10S548 43.4 2.72 1.85
19 * 106.7 * 2.69
19 D19S210 108.6 0.31 3.01
LOD scores were calculated from empirical P values. *Interval
between adjacent markers.
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27.8%) (Fig. 3). The effective number of independent SNPs
with MAF $0.1% was estimated as 1,578, resulting in
a signiﬁcance threshold of P value ,3.17 3 1025 after
correction for multiple testing.
Targeted Sequencing of the CACNB2 Gene and
Validation by Genotyping the Mutations
The sequencing analysis of CACNB2 exons in 45 case
subjects with PDR identiﬁed two missense mutations at
the COOH-terminal half of the protein in the last exon of
the CACNB2 gene. We identiﬁed a point mutation of C to
T resulting in a substitution of arginine for cysteine
(rs202152674/R476C) and another point mutation of
C to T resulting in a substitution of serine for leucine
(rs137886839/S502L) in CACNB2 (ENST00000396576),
with both mutations identiﬁed once. MutationTaster (21)
predicted both mutations to have an impact on the protein
function (disease causing); PolyPhen predicted both var-
iants to probably be damaging, while SIFT predicted R476C
to be deleterious (with low conﬁdence) and S502L as
tolerated.
In the genome aggregation (GnomAD) database
(gnomad.broadinstitute.org), the rs202152674/R476C and
rs137886839/S502L variants showed 0.02% and 0.3%
allele frequency in the Finnish and 0.009% and 0.02%
in the non-Finnish Europeans, respectively. The allele
frequencies of both variants were the highest in the
East Asian populations, 0.2% and 1%, respectively. There-
fore, we sought in silico replication of these variants in
11,097 Japanese individuals with type 2 diabetes (17).
However, no copies of the variants were identiﬁed.
We genotyped the identiﬁed missense variants in 3,052
subjects with type 1 diabetes. Heterozygous genotypes for
R476C and S502L of one sib pair already sequenced with
NimbleGen sequencing were veriﬁed, and a total of seven
individuals were heterozygous for the R476C mutation
and 15 individuals heterozygous for the S502L mutation
(Table 3). Targeted sequencing veriﬁed the genotypes for
R476C and S502L mutation carriers. Approximately 30%
of both R476C and S502L carriers had PDR. While very
sparse ophthalmic data were available for the other R476C
carriers, 20% of the S502L carriers had only mild retinop-
athy, and 20% had no retinopathy despite long duration
($15 years) of diabetes.
For each individual with a mutation, four control sub-
jects were matched for age, sex, and duration, but no
differences occurred between the case and the control
subjects except for higher total cholesterol values in those
with the S502L mutation (5.41 mmol/L) compared with
the matched control subjects (4.79 mmol/L) (P 5 0.047)
(Supplementary Table 4). Interestingly, the mean duration
of diabetes to PDR was ;16–17 years in the S502L and
R476C carriers, while the average (SD) in the FinnDiane
population is 21.4 (7.6) years, suggesting that PDR devel-
ops faster in the mutation carriers. However, formal
survival analysis was not calculated because of the small
number of observations.
CACNB2 gene expression was detected in multiple
tissues, including retina, in the Functional Annotation
of Mammalian Genomes (FANTOM5) data (30). CACNB2
encodes the b2 subunit of the L-type calcium channel.
While the channel can have one of the b1, b2, b3, or b4
subunits, the b2 subunit has the highest mRNA expression
in retina (37.8 tags per million [tpm] vs. b1, 6.9 tpm; b3,
9.3 tpm; and b4, 8.5 tpm).
Functional Role of the CACNB2 Gene in Retinal
Pigmented Cell
To explore the role of the CACNB2 gene for the function
of the L-type Ca21 channels, we tested the expression of
the CACNB2 gene in undifferentiated retinal origin cells,
ARPE19 and MIO-M1 cells. CACNB2 was abundantly
Figure 2—The results of multipoint genome-wide linkage study on chromosome 10. The genetic distance (cM) is plotted on the x-axis against
the LOD score on the y-axis. Diamonds indicate the LOD scores from the multipoint analysis; the star indicates the single-point LOD score
of 2.73 for the microsatellite D10S548 at 43.4 cM.
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expressed at the mRNA level in ARPE19 cells (Fig. 4A) and
at the protein level in ARPE19 and MIO-M1 cells (Fig. 4B).
Additionally, we found a 12-fold higher expression of
CACNB2 mRNA in the differentiated hESC-RPE compared
with undifferentiated ARPE19 cells (Fig. 4C). Based on the
ﬁndings from a previous study, where the authors showed
a role of L-type Ca21 channels for the regulation of VEGF
secretion in normal retinal pigmented epithelium (RPE)
cells (31), we knocked down the CACNB2 by using RNA
interference, which led to a signiﬁcant decrease in the
Figure 3—Regional summary of the association, linkage, and sequencing ﬁndings for PDR on chromosome 10p12 CACNB2 locus.
The LocusZoom plot (54) with the2log10 (P values) on the y-axis corresponds to the association analysis P value. The SNP with the lowest
P value (P 5 8.6 3 1024) is depicted in lilac, and the r2 color coding illustrates the linkage disequilibrium with this SNP. Arrows indicate the
locations of the D10S548 microsatellite and of the identiﬁed missense mutations. Recombination rates can be seen in blue. Chromosome
positions are based on hg19/1000 Genomes November 2015 EUR.
Table 3—The genotyping results showed that 7 individuals were found with the R476C mutation and 15 individuals with the
S502L mutation
R476C, rs202152674 S502L, rs137886839
Alleles (minor/major) T/C T/C
n (heterozygotes) 7 15
MAF, % 0.1 0.2
Male sex 3 (43) 5 (33)
Fundus photographs or ophthalmic records available 3 (43) 14 (93)
Laser treatment 2 (29) 4 (27)
PDR 2 (29) 5 (33)
Duration of diabetes to PDR (years)* 15.8 (13.7–17.9) 16.7 (13.0–20.0)
Nonproliferative diabetic retinopathy 1 (14) 3 (20)
No diabetic retinopathy, duration $15 years 0 3 (20)
No diabetic retinopathy, duration ,15 years 0 3 (20)
Diabetes duration at the time of latest ophthalmic information (years) 30.3 (19.8–40.8) 20.7 (10.7–40.3)
Data are median (range) or n (%) unless otherwise indicated. *Duration of diabetes to PDR is calculated among the participants with PDR.
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Figure 4—In vitro expression and effect of CACNB2 knockdown. A: Semiquantitative RT-PCR to show endogenous expression of different
splice variants (b2a, b2b, b2c, b2d, b2e) of CACNB2 in ARPE19 cells. Last exon is common in all variants. Total CACNB2 expression
was detected by primers designed to amplify a region in last exon. Porphobilinogen deaminase (PBGD) was used as housekeeper in the
same expression range as CACNB2. bp, base pairs. B: Western blot showing expression of endogenous CACNB2 protein in ARPE19 and
MIO-M1 cells. KD, kilodalton. C: Quantitative RT-PCR to show expression of CACNB2 mRNA in human stem cell–derived differentiated
mature retinal pigmented cells (dRPEs) compared with undifferentiated ARPE19 cells. N5 3. D: Change in CACNB2 and VEGFmRNA after
knocking down CACNB2 using siRNAs against CACNB2 compared with nontargeting siRNA control in ARPE19 cells. We observe
statistically signiﬁcant downregulation of CACNB2 mRNA impacting level of VEGF mRNA (P value ,0.01). N 5 3. E and F: VEGF ELISA
shows signiﬁcantly less secreted VEGF in ARPE19 and MIO-M1 cell medium (P value ,0.01). Differences in siRNA knockdown levels are
attributed to varied transfection efﬁciencies between cell lines. N 5 3.
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VEGF mRNA levels (Fig. 4D) and almost twofold decrease
in the VEGF secretion by ARPE19 cells in culture medium
(Fig. 4E). Furthermore, we knocked down CACNB2 in the
Müller cell line (MIO-M1), as Müller cell–derived VEGF
has been shown to play a crucial role in diabetes-induced
inﬂammation and vascular leakage (32,33). We observed
;30% reduction in the secreted VEGF protein in cell
culture medium of CACNB2 knockdown cells compared
with control scrambled siRNAs.
DISCUSSION
In linkage analysis of type 1 diabetes sib pairs, we detected
evidence of linkage (LOD score 2.73) between PDR and
chromosome 10p12 (D10S548 in CACNB2). Subsequent
candidate gene association analysis showed the lowest
P value for PDR at rs11014284 (P 5 8.6 3 1024) in the
vicinity of D10S548. By next-generation sequencing, we
discovered two missense mutations (R476C/rs202152674
and S502L/rs137886839) predicted to have an impact on
the protein function and located in the same region as the
linkage and the association ﬁndings (Fig. 3). Even though
the two CACNB2 variants do not seem to have any major
inﬂuence on PDR, as the mutations occurred only in a few
individuals, we nevertheless speculate that the variants
may play a role in the pathogenesis of PDR: the individuals
with the mutation had indeed a shorter mean duration of
diabetes until PDR (16–17 years) compared with the rest
of the FinnDiane population (21 years), despite a similar
PDR prevalence (33% of 1,117 FinnDiane individuals
[34]). The R476C mutation is of particular interest, since
introduction of an additional cysteine residue may dis-
turb the usual pairing of cysteine residues and lead to
the formation of unnatural disulﬁde bonds within the
multimers.
Many tissues express CACNB2 in the inner surface
of the cell membrane, and gene expression was detected
in the retinal tissue; furthermore, CACNB2 was detected in
the ARPE19 cell line, iPSC-derived RPE cells, and MIO-M1
cell line. It is of note that alternatively spliced variants of
the gene have been identiﬁed (35). Interestingly, the
CACNB2 knockout is associated with night blindness
and altered retinal morphology in mice, while knockout
of the alternative b1, b3, or b4 subunits did not show any
effect (36). CACNB2 has also been linked to the Brugada
syndrome (i.e., abnormal electrical activity within the
heart) (37), sudden cardiac death syndrome with arrhyth-
mia, hypertension (38), Alzheimer disease, and migraine in
man (39,40). In addition, GWAS showed association be-
tween a number of psychiatric disorders (autism spectrum
disorder, attention deﬁcit-hyperactivity disorder, major
depressive disorder, bipolar disorder, and schizophrenia)
and CACNB2 (41).
The CACNB2 gene encodes the b2 subunit of the L-type
voltage-dependent calcium channel. Interestingly, only the
L-type voltage-dependent calcium channels are sensitive to
calcium channel blockers that are used as antihypertensive
treatment (31). CACNB2 may be involved in the patho-
genesis of PDR through a pathway by which calcium
channels regulate vascular endothelial growth factor
(VEGF) expression and release in the retinal pigment
epithelium (31,42); in particular, previous work shows
that the L-type Ca21 channels participate in the regulation
of VEGF secretion in hESC-RPE cells (43). Furthermore,
our CACNB2 knockdown experiments in ARPE19 and
MIO-M1 cell lines show its role in VEGF regulation in
these cells. VEGF, in turn, plays an essential role in
angiogenesis and the development of diabetic retinal neo-
vascularization by increasing delivery of oxygen and energy
substrates (44–46) and is thereby involved in stimulating
microaneurysm formation, capillary occlusion, and en-
hancement of vascular permeability at the early stages
of diabetic retinopathy (47). Inhibition of VEGF prevents
ocular neovascularization in animal models. From the
clinical point of view, it is of note that anti-VEGF treat-
ment is used to treat macular edema in humans and is also
considered a potential treatment for PDR (48). Long-term
results are, however, still lacking.
While the highest linkage peak was located within the
CACNB2 gene, it should be noted that the 10p12 region
contains 48 additional protein-coding genes; variants near
two of these genes, PLXDC2 and MALRD1, located 500 kb
from CACNB2, have been suggestively associated with
diabetic retinopathy in individuals with type 2 diabetes
in GWAS studies (49,50). PLXDC2 is involved in endothe-
lial cell angiogenesis and may thus play a role in mediating
the development and progression of diabetic retinopathy
similarly as VEGF (51,52). Altogether, GWAS have iden-
tiﬁed only a very few loci for PDR despite substantial
reported heritability (10,11). Of note, GWAS on PDR are
limited in number of participants at the discovery stage—
at the most, a few thousand, very few GWASmeta-analyses
have so far been published, and only a few genome-wide
signiﬁcant ﬁndings have been successfully replicated in
other studies (12,14).
The major strengths of this study are the large number
of individuals, a comprehensive phenotypic characteriza-
tion of the individuals with type 1 diabetes, and the
availability of both linkage and GWAS data. The sample
size is crucial in association studies because the statistical
power is enhanced with larger sample sizes. We had
a reasonably large sample size in comparison with other
genetic studies on PDR (11), considering that both the
PDR case and the control subjects had to have type
1 diabetes. By using both family-based and case-control
approaches, we covered both genetic linkage and associa-
tion based on linkage disequilibrium. What makes the
ﬁndings of this study interesting is that the linkage ﬁnding
suggests a rare variant with high penetrance, but it also
replicates as an association with a common variant. The
common variant, however, is probably not directly re-
sponsible for the disease susceptibility; it is more likely
that it is in linkage disequilibrium with the truly func-
tional variant. Further functional studies are required to
2172 CACNB2 Is Linked to Diabetic Retinopathy Diabetes Volume 68, November 2019
understand the role of these variants in the susceptibility
to DR.
A weakness of this study is the lack of replication of the
two identiﬁed missense mutations in other studies. While
they are rare in the European population, both were
identiﬁed with a slightly higher frequency in East Asian
populations (MAF 0.2% and 1% for rs202152674/R476C
and rs137886839/S502L, respectively). However, nei-
ther variant was found in the in silico replication data
in .11,000 Japanese individuals with type 2 diabetes.
Another limitation of this study is that the classiﬁcation of
diabetic retinopathy is based on the presence or absence of
laser-treated retinopathy. Laser treatment correlates with
PDR, but laser treatment can be given already at earlier
stages for severe nonproliferative retinopathy or macular
edema. We have previously shown that in individuals with
type 1 diabetes, the majority (.80%) of laser treatment is
due to PDR (15). Furthermore, the reason for laser treat-
ment was conﬁrmed to be PDR in the sib pair analysis.
Control subjects used in the candidate gene association
analysis were required to have at least 15 years’ duration of
diabetes without PDR. This limit was chosen because the
incidence peak of PDR may occur already at 15–20 years
after the onset of diabetes, as shown in the Wisconsin
study (2). However, the incidence reported in these older
studies may not reﬂect the PDR incidence today, as there
seems to be a declining trend in the cumulative incidence
of PDR (53).
In summary, we found evidence of linkage and associ-
ation between PDR and a novel locus on 10p12 in the
CACNB2 gene and a role of CACNB2 in VEGF secretion in
cell cultures. In addition, two missense mutations were
identiﬁed in the same locus. While the role of CACNB2 has
previously been described for retinal phenotypes in mouse
knockout models, this is the ﬁrst report linking genetic
variation in CACNB2 to human PDR. As calcium channel
blockers targeting the L-type calcium channels are already
in clinical use to treat hypertension, and calcium channels
regulate VEGF, these ﬁndings on CACNB2 open up novel
translational possibilities for treatment of human PDR.
Additional functional studies are being carried out in our
laboratory to further understand the role of these CACNB2
mutations in the pathogenesis of PDR.
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